BASF’s Multifront Week: Analyst Optimism, Price Hikes, and a Renewed Legal Push Against Apple

The German chemicals giant is navigating a dense stretch of corporate activity, with developments arriving simultaneously across the capital markets, its North American pricing strategy, and the U.S. courtroom. The convergence of these threads — bookended by a fresh analyst endorsement and a second patent infringement suit against one of the world’s most valuable technology companies — paints a picture of a conglomerate pressing its advantages on several fronts at once.

Citigroup became the latest voice of optimism on September 3, lifting its price target on BASF shares to EUR 60 from EUR 58 while reaffirming a Buy recommendation. The adjustment lands as the stock trades with notable momentum: the equity closed Friday’s session at EUR 53.33, a modest 0.2 percent dip on the day, yet the broader trajectory remains firmly upward. Over the past 30 days, the shares have advanced 5.3 percent, and they now stand roughly 20 percent higher since the start of the year.

That performance leaves BASF hovering just 3.1 percent beneath its 52-week peak of EUR 55.05, a level reached on April 14. Technical indicators reinforce the constructive picture — the stock sits comfortably above both its 50-day moving average of EUR 49.98 and the 200-day average of EUR 48.89, the latter a widely watched gauge of the medium-term trend. Not every analyst shares Citigroup’s enthusiasm, however. A day earlier, on September 2, MWB Research downgraded the shares from Buy to Hold, citing what it described as a now-normalized risk-reward profile.

The analyst chatter is unfolding against a backdrop of operational maneuvering. BASF implemented a series of price increases across North America effective September 1, covering caprolactam, polyamide 6, and polyamide-6/66 copolymers — key upstream materials for plastics and fibers. The adjustments, announced in late August, include a hike of USD 0.08 per pound for those products. Simultaneously, the company raised prices for neopentyl glycol (NPG) in both Europe and North America. These moves signal an effort to pass through elevated raw material and energy costs, and their success will be measured by how effectively BASF can exercise pricing power in a chemical market that has recently seen uneven demand.

Should investors sell immediately? Or is it worth buying BASF?

On the legal front, BASF filed a new patent infringement complaint against Apple in the United States on September 3, alleging that the tech giant’s Face-ID and facial authentication technology in iPhones and iPads infringes on BASF-held patents. The filing, reported by Reuters and picked up widely across financial media, marks the second such legal salvo in an ongoing dispute between the two companies. For shareholders, the practical implications are difficult to gauge — patent litigation of this sort routinely stretches over years and frequently concludes with licensing arrangements rather than courtroom verdicts. Near-term share price impact is likely minimal, but the case underscores BASF’s willingness to defend its intellectual property beyond the boundaries of its core chemical operations.

A quieter piece of news rounded out the week: on September 1, BASF received the Ringier Technology Innovation Award 2026 for its Plantapon Amino ASP product in the Functional Chemicals – Surfactants category. While unlikely to move the needle for investors, the recognition highlights the company’s innovative output in specialty chemicals, a segment that complements its larger petrochemicals and materials divisions.

Taken together, the week’s events show a company simultaneously pursuing pricing discipline, legal assertiveness, and product innovation. With a market capitalization of EUR 45.94 billion, BASF continues to command attention — and its shares, trading near annual highs with analyst support from at least one major bank, suggest the market is taking note.